targets a conserved E2F transcription factor-binding site 546 bp upstream of the transcription start site (Supplementary Table 3 ). All 32 cases analyzed showed the pattern for unmethylated DNA like the controls (data not shown).
In this study, we identified biallelic inactivation of TRAF3 (9/41, 22%) and lower expression of TRAF3 mRNA in B-cell neoplasias with deletion del(14)(q24.1q32.33) due to breaks in IGH and ZFP36L1 regions. Abnormalities that inactivate the TRAF3 protein lead to constitutive NF-kB activation, 4, 6 which is a known mechanism in various cancer types to block apoptosis. 8 The ring finger domain and the TRAF3 domain are the critical components of TRAF3 for the suppression of NIK protein levels and the subsequent inhibition of NF-kB2. 7 At least one of the two domains is affected in each of the three TRAF3-mutated alleles, suggesting TRAF3 inactivation in these cases. The fact that we observed cases with subclonal homozygous deletion of the second TRAF3 allele indicates that this loss occurred secondary during tumor progression. It is still possible that oncogene activation through juxtaposition of IGH in 14q32.33 to the chromosomal region in 14q24.1 is the major mechanism in lymphomagenesis conferred by the deletion del(14)(q24.1q32.33). Complete loss of functional TRAF3 by inactivation of the remaining allele may induce a further selective advantage of the tumor cells. B-cell-specific TRAF3 À/À mice show an increased production of immunoglobulins. 7 Therefore, it is intriguing to speculate that loss of functional TRAF3 in cases with deletion del(14)(q24.1q32.33) leads to stronger activation of the immunoglobulin enhancer and, subsequently, a stronger activation of a putative oncogene in 14q24 that is juxtaposed to the IGH locus.
Conflict of interest
The authors declare no conflict of interest. Imatinib mesylate (Glivec/Gleevec, STI571; Novartis, Basel, Switzerland) is a 2-phenylaminopyrimidine-based ATP-competitive protein tyrosine kinase inhibitor, which at pharmacologically-achievable concentrations inhibits the activity of BCR-Abl, 1 stem cell factor receptor (c-Kit), 2 platelet-derived growth factor receptor (PDGFR)-a and PDGFR-b 1 and the macrophage colony-stimulating factor receptor, c-fms (CSF-1R). 3 Imatinib is a highly effective treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours, based on the inhibition of BCR-Abl and c-Kit, respectively. Although imatinib is the gold standard therapy for CML in adults, it is only approved for use in paediatric CML cases in which disease recurrence is evident after allogeneic stem cell transplantation, or when paediatric patients show resistance or intolerance to interferon-a therapy. Increasingly, imatinib is used as a front-line therapy in newly diagnosed paediatric CML patients for whom HLA-identical donors are not available.
CML is rarely seen in children and accounts for less than 3% of childhood leukaemias. 4 Given this low incidence, it has not been feasible to conduct large-scale phase III trials to determine the long-term effects of imatinib therapy in the paediatric setting. However, although short-term imatinib therapy has been successful and well tolerated in children, there is emerging information suggesting that long-term therapy may have the potential to result in side effects that are specific to the paediatric setting.
Two recently published case studies report decelerated growth in juvenile CML patients undergoing imatinib therapy. 5, 6 Mariani et al. described a case of an 11-year-old boy who experienced a dramatic reduction in growth rate from 4.3 to 1.5 cm per year after commencing imatinib therapy. Although normal growth recommenced at the onset of puberty, 2 years after imatinib treatment began, the correlation of the onset of growth retardation with onset of imatinib therapy suggested a Figure 1 The growth plate at the proximal tibia is narrowed in imatinib-treated animals. Female Sprague-Dawley rats (9 months old) were treated for 12 weeks with imatinib (100 mg/kg/day) or vehicle (10% DMSO/90% PEG 300). Six animals per group were culled at 4, 8 and 12 weeks and tibiae were collected for histological analysis and mCT analysis. (a) Left tibiae were mCT scanned at 74 kV/100 mA, with an isometric resolution of 8.7 mm per pixel using a 1 mm aluminium filter and two frame averaging. Reconstruction of the original scan data was performed using NRecon (SkyScan) and analysis of percentage of bone volume relative to total volume (BV/TV) was performed using CTAn (SkyScan) in a 1.744 mm long hand-drawn region of interest spanning 100 slices on either side of the growth plate and excluding the cortex. (b) Right tibiae were harvested and immediately fixed in 10% neutral-buffered formalin (NBF) at 4 1C for 48 h followed by decalcification for 5 months using 0.5 M EDTA/0.5% formaldehyde (pH 8.4) at 4 1C (changed three times per week). Samples were embedded in paraffin and 5 mm sections were stained with Safranin O/Fast Green. Growth plate thickness was measured at five equidistant points along the growth plate. (c) Representative images are shown of Safranin O-stained sections (red, cartilage [glycosaminoglycans]; green, bone and cytoplasm; purple, nuclei). Bar: 100 mM. Graphs depict mean ± s.e.m. (n ¼ 4-6). *Po0.05, **Po0.001, ***Po0.0001 (Student's t-tests).
Letters to the Editor causative link. A second report described a 6-year-old girl whose growth velocity decreased after beginning imatinib therapy for CML. 5 During 4 years of imatinib therapy, the patient's height increased only marginally, from 114 to 121 cm, with a corresponding decrease in s.d. score from À0.7 to À2.7. Furthermore, when imatinib therapy ceased, the patient's growth rate rapidly increased. Although these studies suggest that imatinib therapy in pre-pubertal individuals may retard growth, there are currently no preclinical reports suggesting a mechanism for altered growth in imatinib-treated paediatric patients. In this study, we describe growth plate changes observed in female Sprague-Dawley rats treated with imatinib by daily oral gavage for up to 12 weeks.
Nine-month-old female Sprague-Dawley rats (n ¼ 36) were obtained from the division of Veterinary Services, IMVS (Adelaide, Australia). Rats were provided standard commercial rat chow and tap water ad libitum. All procedures were approved by the Animal Ethics Committees of the University of Adelaide and of the IMVS. Animals were randomly assigned to two groups and were treated by daily gavage with either 35 mg imatinib (equivalent to approximately 100 mg/kg) in 10% DMSO/90% polyethylene glycol [PEG]300 vehicle (n ¼ 18) or vehicle alone (n ¼ 18). After 4, 8 and 12 weeks of treatment, six animals from each group were humanely killed by CO 2 overdose for micro-computed tomography and histological analysis.
Although micro-computed tomography analysis (Skyscan 1076 X-ray Microtomograph, Skyscan, Aartselaar, Belgium) revealed no change in total trabecular bone volume at the growth plate after 12 weeks of imatinib treatment, when compared with controls (Figure 1a) , the cartilaginous and trabecular architecture was substantially altered in the imatinib-treated animals. In vehicle-treated controls, the width of the cartilaginous growth plate at the proximal tibia remained constant at all time points examined (P ¼ 0.0702, one-way analysis of variance; Figure 1b) . In contrast, the width of the growth plate decreased substantially over time in imatinibtreated animals. The growth plate was significantly narrower in the imatinib-treated group than in the control group after 4 weeks (115 ± 4 cells per well) were cultured on 96-well plates in media containing ascorbate-2-phosphate (100 mg/ml). Following overnight adhesion, the cultures were treated with the indicated doses of imatinib (containing 0.05% DMSO vehicle) or vehicle alone. After 48 h, treatment media were replaced with 100 ml of media containing 1 mCi 35 SO 4 and the plates were incubated overnight. The matrix was then digested at 65 1C for 2 h with 20 U/ml papain digest solution containing 0.1 M sodium acetate, 2.4 mM ethylenediaminetetraacetic acid and 20 mM N-acetyl-L-cysteine. Glycosaminoglycans (GAG) were precipitated with 10 mg/ml cetylpyridinium chloride in 10% ethanol containing 67 mg/ml chondroitin sulphate A as a carrier. 9 The amount of 35 SO 4 -labelled GAG was then measured using a scintillation counter (a). In replicate cultures, cells were digested in 100 U/ml papain digest solution and DNA content was measured using Hoecht 33258 dye, as described previously, 10 as a surrogate marker of cell number (b). GAG levels were then normalized to DNA content to determine relative GAG production per cell (c). ATDC5 cells were cultured overnight on 96-well plates and were then treated with vehicle (V) or 4 mM imatinib (I) with or without 100 ng/ml recombinant human PDGF-BB. After 48 h, GAG levels (d) and DNA content (e) were quantitated and GAG production per cell was calculated (f). Graphs depict mean ± s.e.m. of three independent experiments (a-c) or mean±s.e.m. of triplicate wells of a representative experiment (d-f) normalized to vehicle controls. *Po0.05; **Po0.01, ***Po0.001 (One-way analysis of variance with Dunnett's post-test, a-c;) (Student's t-tests, d-f).
treatment. By 12 weeks of treatment the growth plate had almost completely fused and was replaced by trabecular bone (Figure 1c) .
In normal growing bone, cartilage thickness at the growth plate is determined by the rate of chondrocyte recruitment and proliferation, the rate of cartilage deposition by chondrocytes and the lifespan of the cartilage before it is mineralized and replaced by the trabecular bone. 7 Longitudinal bone growth, however, is primarily determined by the rate of chondrocyte proliferation. 7 To determine whether imatinib can directly affect chondrocyte proliferation or activity, we examined the effects of imatinib on the murine pre-chondrocyte cell line ATDC5 8 in vitro. After 48 h of imatinib treatment, a significant decrease in the production of glycosaminoglycan (GAG) was observed at 1 mM imatinib and higher (Po0.05; Figure 2a ). This was associated with a significant decrease in cell number, as determined by DNA content per well, at concentrations of 0.5 mM imatinib or greater (Po0.05; Figure 2b) . On a per cell basis, GAG production was significantly inhibited at 0.5 mM imatinib, relative to vehicle controls (Po0.05; Figure 2c ).
PDGF-BB treatment has been shown to increase cell proliferation and activity of resting zone chondrocytes derived from Sprague-Dawley rats. 11 In addition, PDGF-BB increases the proliferation, but not the rate of GAG production per cell, of chondrocytes isolated from bovine occipital cartilage. 12 These results suggest that imatinib treatment may have direct effects on chondrocyte proliferation and, in some cases, activity through inhibition of PDGFR-b. We next examined whether the inhibition of ATDC5 proliferation and GAG production was due to an inhibition of PDGFR-b. Under the conditions used here, treatment with 100 ng/ml recombinant human PDGF-BB induced a 3.5-fold increase in GAG levels (Po0.0001; Figure 2d ). This was attributable to both an increase in cell numbers, as assessed by DNA levels (Po0.05; Figure 2e ), and induction of GAG synthesis on a per cell basis (Po0.01; Figure 2f ). These effects were partially reversed by addition of 4 mM imatinib (Po0.05; Figures 2d-f) .
Taken together, these results suggest that inhibition of PDGFR-b signalling by imatinib may contribute to the observed decreased growth plate thickness and decreased longitudinal bone growth through the inhibition of chondrocyte proliferation and activity. In addition, as imatinib activates osteoblast differentiation but inhibits the proliferation of osteoblast precursors in vitro, at least in part through inhibition of PDGFR signalling, 13 the results may also be attributable to altered mineralization dynamics at the growth plate.
To our knowledge, this is the first report to describe a potential mechanism for the observed perturbation of growth seen in two juvenile patients undergoing imatinib therapy. Growth plate closure in normal situations is a marker of growth cessation, rather than a cause of it. 7 It is not clear from this study whether the rapid acceleration of growth plate closure observed is merely associated with a growth inhibitory effect of imatinib therapy or is a mechanism by which imatinib therapy causes decreased growth. In the two reported cases of delayed growth in imatinib-treated pre-pubescent patients, bone age (based on X-rays of the wrist or hand) was delayed 5 or normal, 6 suggesting that premature growth plate closure at these sites was not detected. However, this does not rule out the possibility that growth plates were affected at other sites. In any case, the dramatic effect of imatinib on growth plate closure in rats suggests that growth plate morphology should be monitored in juvenile patients undergoing imatinib therapy, and should be investigated as a potential mechanism for inhibited growth in pre-pubescent patients receiving imatinib. The increasing use of imatinib therapy as a front-line treatment for CML in the paediatric setting necessitates elucidation of the potential growth effects of imatinib.
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12 Weiser L, Bhargava M, Attia E, Torzilli PA. Effect of serum and platelet-derived growth factor on chondrocytes grown in collagen gels. Tissue Eng 1999; 5: 533-544. Acute megakaryoblastic leukemia (AMKL) is a biologically and cytogenetically heterogeneous subtype of acute myeloid leukemia. AMKL either presents de novo or as therapy-related leukemia after chemotherapy or as a leukemic transformation of chronic myeloproliferative neoplasms. The incidence of AMKL in adult de novo acute myeloid leukemia patients is estimated to be about 1-2%, whereas the incidence in the pediatric population is as high as 5-7%, largely because of its association with Down's syndrome (DS). 1,2 DS-AMKL and non-DS-AMKL have vastly different genetic abnormalities and outcomes. Although patients with DS-AMKL have a favorable prognosis, with a 5-year event-free survival rate between 70 and 80%, children with non-DS-AMKL fare much worse, with a 5-year event-free survival of 22-28%. 2, 3 Similarly, the prognosis of adult AMKL is dismal, with a median survival of B10 months. 1 With respect to the molecular basis for megakaryocytic subtypes of acute myeloid leukemia, DS-AMKL blasts uniformly harbor trisomy 21 and somatic mutations in the X-linked hematopoietic transcription factor, GATA1.
4 Distinct abnormalities, such as t(1;22)(p13;q13), which leads to expression of the OTT-MAL (RBM15-MLK1) fusion protein, t(10;11), t(9;11) or þ 8 are seen in cases of non-DS pediatric AMKL. 4 However, very little is known about the etiology of adult AMKL, as no specific chromosomal rearrangements or genetic mutations have been described, apart from a rare detection of mutations in c-MPL, c-KIT, JAK2, JAK3 or FLT3. [4] [5] [6] Leukemia is caused through a multistep process involving genetic alterations that lead to both a proliferative advantage and a block in terminal differentiation. With respect to DS-AMKL, it is likely that trisomy 21 provides a proliferative advantage to fetal hematopoietic progenitors that harbor GATA1 mutations and that these two alterations are sufficient enough to cause TMD (transient myeloproliferative disorder), a preleukemia that is characterized by an aberrant expansion of megakaryoblasts in the fetal liver and peripheral blood. However, trisomy 21 and GATA1 mutations alone are not sufficient to cause DS-AMKL. Consistent with this model, recent studies have shown that DS-AMKL blasts harbor rare activating mutations in FLT3, JAK2, JAK3 and c-MPL. 5, 6 Despite these new insights, the specific genetic events that cooperate with GATA1 and trisomy 21 in the evolution of AMKL are largely unknown. Moreover, common recurrent genetic abnormalities present in pediatric non-DS AMKL and adult AMKL have not been defined.
To identify novel mutations that are associated with AMKL, we systematically analyzed a cohort of 16 adult non-DS-AMKL (diagnosed by immunophenotype and/or French American British (FAB) criteria) patient samples (Table 1) by nucleotide sequence analysis for mutations in genes that are associated with hematopoietic disorders (FLT3, PTEN, c-MPL, PTPN11 and JAK1) and genes that are implicated in normal megakaryocytic differentiation (NOTCH1, GATA2, ETS2, ERG, MEF2C, GABPA, TEL and FLI1). We assayed all the coding regions of these genes by sequencing with the following exceptions: for NOTCH1, we analyzed sequences that encode the heterodimerization and peptide signal rich in proline, glutamic acid, serine, threonine Table 1 Characteristics of AMKL specimens used in this study Letters to the Editor
